On 1 April 2008 , orphan designation (EU/3/08/535) was granted by the European Commission to Chiltern International Limited, United Kingdom, for humanised monoclonal antibody to the folate receptor alpha for the treatment of ovarian cancer.
The sponsorship was transferred to Eisai Europe Limited, United Kingdom, in June 2010. The sponsorship was transferred to Eisai GmbH, Germany, in September 2018.
The sponsor’s address was updated in August 2020.
Humanised monoclonal antibody to the folate receptor alpha
|Disease / condition||
Treatment of ovarian cancer
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.